Zacks Research Has Bearish Estimate for Glaukos Q2 Earnings

Glaukos Corporation (NYSE:GKOS) – Equities research analysts at Zacks Research lowered their Q2 2027 EPS estimates for shares of Glaukos in a report issued on Wednesday, August 19th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings per share of $0.06 for the quarter, down from their prior forecast of $0.07. The consensus estimate for Glaukos’ current full-year earnings is ($0.35) per share. Zacks Research also issued estimates for Glaukos’ Q3 2027 earnings at $0.10 EPS, Q4 2027 earnings at $0.33 EPS, FY2027 earnings at $0.45 EPS, Q1 2028 earnings at $0.18 EPS, Q2 2028 earnings at $0.37 EPS and FY2028 earnings at $1.70 EPS.

GKOS has been the subject of a number of other reports. Truist Financial boosted their price target on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. HC Wainwright increased their price objective on Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Needham & Company LLC lifted their price objective on Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Citigroup boosted their target price on shares of Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Wells Fargo & Company upped their target price on shares of Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.33.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $189.72 on Thursday. The business’s fifty day moving average price is $154.98 and its two-hundred day moving average price is $130.78. The stock has a market cap of $11.19 billion, a PE ratio of -58.38 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. Glaukos has a one year low of $73.16 and a one year high of $190.06.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm had revenue of $185.61 million during the quarter, compared to the consensus estimate of $150.93 million. During the same period in the previous year, the firm posted ($0.24) EPS. The company’s quarterly revenue was up 49.6% compared to the same quarter last year.

Insider Activity

In other news, CFO Alex R. Thurman sold 20,000 shares of Glaukos stock in a transaction on Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the completion of the sale, the chief financial officer owned 43,906 shares of the company’s stock, valued at $7,908,787.78. The trade was a 31.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 60,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. The trade was a 45.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 110,525 shares of company stock valued at $19,125,006 over the last quarter. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Glaukos

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Glaukos during the second quarter worth approximately $1,333,318,000. Janus Henderson Group PLC grew its stake in shares of Glaukos by 77.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock valued at $575,844,000 after buying an additional 2,329,608 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Glaukos during the 2nd quarter valued at $679,614,000. Wellington Management Group LLP increased its holdings in shares of Glaukos by 10.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after buying an additional 336,266 shares during the last quarter. Finally, Primecap Management Co. CA increased its holdings in shares of Glaukos by 49.8% during the 4th quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after buying an additional 1,123,140 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Zacks Research raised multiple long-term EPS forecasts. Estimates increased for FY2027 EPS to $0.45 from $0.38, FY2028 EPS to $1.70 from $1.56, Q4 2027 EPS to $0.33 from $0.30, Q1 2028 EPS to $0.18 from $0.16, and Q2 2028 EPS to $0.37 from $0.32. The revisions suggest stronger expected profitability as Glaukos scales its business. Zacks Research article
• Positive Sentiment: Growth catalysts remain intact. Zacks highlighted Glaukos’ iDose TR and Epioxa products, margin-expansion potential, and broad development pipeline as reasons to retain the stock. These factors support the long-term growth narrative behind GKOS.
• Neutral Sentiment: Management will participate in the Wells Fargo Healthcare Conference on September 9, 2026. The event could provide updates on product launches, clinical programs, and financial goals, although no new operating information was announced. Glaukos Wells Fargo Healthcare Conference announcement
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q2 2027 EPS forecast to $0.06 from $0.07, indicating some modest pressure in the intermediate outlook. However, the cut was outweighed by increases to most other quarterly and annual forecasts.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.